Financial Results & Reports
ViroGates’ current and previous financial results, reports, analyst presentations, IPO documents, and more, are listed below.
Financial Results, Q1-Q3 2022
Annual Report 2021
2021 was an exciting year for ViroGates. The company delivered revenue growth of 43% and achieved extraordinary scientific results. However, the global COVID-19 continued to affect the business negatively with many hospitals unable to onboard new technologies during a state of emergency. Despite the challenges, ViroGates welcomed several new customers across markets and managed to shift sales further towards clinically relevant products.
Previous Interim/Half-Year Reports
Analyst Reports
2022
10 May 2022:Market Focus Update by Västra Hamnen Corporate Finance
25 March 2022:Market Focus Update by Västra Hamnen Corporate Finance
2021
18 November 2021:Market Focus Update by Västra Hamnen Corporate Finance
2020
6 November 2020:Analyse af ViroGates A/S by Aktieinfo
27 October 2020:Market Focus Update by Västra Hamnen Corporate Finance
14 August 2020:Market Focus Update by Västra Hamnen Corporate Finance
30 March 2020: Market Focus Update by Västra Hamnen Corporate Finance
29 January 2020: Market Focus Initial Research by Västra Hamnen Corporate Finance
2019
12 April 2019:Analyse af ViroGates A/S by Aktieinfo
2018
4 October 2018:Analyse af ViroGates A/S by Aktieinfo
IPO 2018 Documents
ViroGates Prospectus 2018 (Full version in English)
ViroGates Prospectus 2018 (Summary in Swedish)
ViroGates Prospectus 2018 Announcement
ViroGates Brochure (in Swedish)
11 June 2018: Presentation at Aktiespararnas Småbolagsdag in Stockholm
12 June 2018: Presentation at InvestorDagen by the Danish Shareholders’ Association in Aarhus